|
May 7
|
Longboard Pharmaceuticals (NASDAQ:LBPH) Is In A Good Position To Deliver On Growth Plans
|
|
May 4
|
Longboard Pharmaceuticals Inc. (LBPH) Q1 2024 Earnings: Financial and Strategic Developments
|
|
May 2
|
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
|
|
May 1
|
Starbucks downgraded, Dollar Tree upgraded: Wall Street's top analyst calls
|
|
Apr 3
|
Longboard Pharmaceuticals to Present Late-Breaking Data from the PACIFIC Study at the American Academy of Neurology (AAN) Annual Meeting on April 15
|
|
Mar 27
|
Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH) is a favorite amongst institutional investors who own 50%
|
|
Mar 14
|
Longboard Pharmaceuticals Inc Reports Full Year 2023 Financial Results
|
|
Mar 12
|
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
|
|
Mar 1
|
Longboard Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
|
|
Jan 2
|
Longboard Pharmaceuticals Announces Positive Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial, for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
|
|
Jan 1
|
Longboard Pharmaceuticals to Host Call to Discuss Topline Data from the PACIFIC Study, a Phase 1b/2a Clinical Trial for Bexicaserin (LP352) in Participants with Developmental and Epileptic Encephalopathies (DEEs)
|
|
Nov 29
|
Longboard Pharmaceuticals Announces Initiation of First-in-Human Phase 1 Clinical Study of LP659 in Adult Healthy Volunteers
|
|
Aug 10
|
Institutional investors own a significant stake of 39% in Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH)
|
|
Aug 3
|
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
|